ArticleAnnals of surgery open : perspectives of surgical history, education, and clinical approaches2026
Distal and Total Pancreatectomy With En Bloc Celiac Axis Resection for Pancreatic Cancer at a High-Volume Center.
Article in Annals of surgery open : perspectives of surgical history, education, and clinical approaches, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study evaluated outcomes after distal and total pancreatectomy with en bloc celiac axis resection (DP-CAR/TP-CAR), and preoperative hepatic artery embolization intended to mitigate postoperative organ ischemia. Background: DP-CAR and TP-CAR are surgical interventions for advanced pancreatic cancer, associated with substantial complication and recurrence rates. Despite advancements in oncologic therapy, the risks and benefits of these extensive procedures remain poorly defined. Methods: Prospectively collected data from patients operated on between January 1, 2014, and June 30, 2025, were analyzed. The primary endpoints included overall survival and recurrence-free survival. Secondary endpoints comprised radicality of resection and incidence of postoperative complications. Results: Of 58 consecutively operated patients, 52 underwent neoadjuvant oncologic treatment. Surgical procedures consisted of DP-CAR (n = 38), TP-CAR (n=11), and exploratory laparotomy (n=9). Uncomplicated preoperative hepatic artery embolization was achieved in 54 patients (93.1%). Pancreatic leaks occurred in 22.2% of cases, whereas organ ischemia was observed in 16.3%. R0 and R1 resection rates were 26.5% and 73.5%, respectively. Median overall survival for patients receiving neoadjuvant oncologic treatment followed by surgery, upfront surgery, and exploratory surgery was 28.0, 23.3, and 20.1 months, respectively. The median recurrence-free survival was 6.0 months (range: 1-43), whereas the median interval from surgery to detection of distant metastases or local recurrence was 5 (range: 1-43) and 13 months (range: 3-32), respectively ( Conclusion: DP-CAR and TP-CAR may be performed with complication rates comparable to standard distal and total pancreatectomies. Nonetheless, the elevated rate of cancer recurrence underscores the necessity of meticulous preoperative patient selection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.